Antitrust Antidote: January-March 2026

Key Takeaways

• Ninth Circuit rules Apple’s data block is a refusal‑to‑deal
• FTC wins preliminary injunction against Edwards Lifesciences merger over pipeline products
• Court rejects CVS tying claim, citing ample pharmacy substitutes
• OWN Your Hunger dismissed for failing to define a relevant market
• Decisions signal growing judicial caution on essential‑facility and forced‑sharing doctrines

Pulse Analysis

The first quarter of 2026 delivered a series of antitrust judgments that underscore the courts’ growing willingness to scrutinize data‑centric strategies and nascent product markets. In the technology arena, the Ninth Circuit’s decision in AliveCor v. Apple marked a rare application of the refusal‑to‑deal doctrine to a software update, rejecting Apple’s claim that product improvement shields it from liability. By treating the Apple Watch’s algorithmic shift as a potential barrier to competition, the court revived concerns about essential‑facility arguments, even as scholars warn that forced data sharing can stifle innovation in fast‑moving sectors.

Healthcare mergers faced equally rigorous analysis. The D.C. district court’s injunction against Edwards Lifesciences’ purchase of JenaValve hinged on the recognition that pre‑commercial TAVR‑AR devices constitute a distinct market under the Brown Shoe practical indicia. This approach departs from the traditional reliance on the Philadelphia National Bank presumption, emphasizing real‑world competition in development pipelines rather than static market shares. The ruling sends a clear signal to medical‑device firms: overlapping pipeline products will be examined for their impact on future innovation, not just current sales.

The pharmaceutical services space saw the dismissal of CVS Health’s alleged tying of its 340B contract‑pharmacy program to the Wellpartner TPA, with the court noting that hospitals can readily switch to other pharmacies. Although CVS commands roughly 32.6% of 340B contracts, patient geography drives pharmacy choice, limiting the practical effect of the tie‑in. Meanwhile, the OWN Your Hunger case highlighted the critical importance of precise market definition; without it, antitrust claims falter. Collectively, these decisions illustrate a judicial trend toward demanding concrete competitive effects and cautioning against broad, doctrine‑driven injunctions, shaping how firms navigate data sharing, mergers, and ancillary service agreements.